title: [Consensus statement of the Croatian Society for Nephrology, Dialysis and Transplantation regarding the use of generic immunosuppressive drugs].
abstract: The use of generic immunosuppressive drugs may decrease the cost of immunosuppressive medication, although total cost sav- ings are still a matter of debate since patients need close monitoring after conversion from original to the generic formulation. A working group of the Croatian Society of Transplantation was established to develop recommendations on the use of generic immunosuppression in renal transplant recipients based on a review of the available data. Immunosuppressive drugs belong to the 'narrow therapeutic index' drugs, with huge pharmacokinetic variations secondary to the impact of food, other drugs, as well as of kidney and liver function. Failure to maintain an appropriate balance of immunosuppression seriously influences graft and patient survival. Published evidence supporting therapeutic equivalence of generic formulations is scarce or completely lacking. Different generic formulations may expose patients to uncontrolled product switching by pharmacists or general practitioners, which is very dangerous for patients, since generic preparations are not required to demonstrate bioequivalence with each other. The Croatian Society for Nephrology, Dialysis and Transplantation is not against the use of generic immunosuppressive drugs, but it requires close supervision of nephrologists and respecting the strict rules of their use. More efforts should be invested in education of primary care physicians as well as of patients to be aware of differences between the original and generic, as well as between different generic formulations.
authors.forename: Nikolina
authors.initials: N
authors.lastname: Bašić-Jukić
authors.forename: Sanjin
authors.initials: S
authors.lastname: Rački
authors.forename: Mladen
authors.initials: M
authors.lastname: Knotek
authors.forename: Ljubica
authors.initials: L
authors.lastname: Bubić-Filipi
authors.forename: Ivan
authors.initials: I
authors.lastname: Bubić
authors.forename: Lada
authors.initials: L
authors.lastname: Zibar
authors.forename: Petar
authors.initials: P
authors.lastname: Kes
mesh_terms: D017523:Croatia; D016568:Drugs, Generic / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006084:Graft Rejection / Q000517:prevention & control*; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D007165:Immunosuppression Therapy / Q000592:standards* / Q000706:statistics & numerical data*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D009398:Nephrology / Q000592:standards*; D011785:Quality Assurance, Health Care / Q000592:standards; D006435:Renal Dialysis / Q000592:standards*; D013810:Therapeutic Equivalency
chemical_list: D016568:Drugs, Generic; D007166:Immunosuppressive Agents